CIS_DSC06188-2 NEWS ROOM arrow-down
News2021-09-29T13:08:44+02:00
211, 2022

CIS Pharma at Festival of Biologics in Basel

Basel, Switzerland, Wednesday, November 2, 2022 – CIS Pharma will attend the Festival of Biologics, Europe’s most exciting biologic’s event, taking place in Basel. The team is looking forward to learn more from leading CDMOs, CROs, Biotech, Pharma and Academia about the latest trends in therapeutic use and manufacturing of biologics. Christian Geraths, CSO and Christoph Schäfer, CEO, Daniela [...]

2410, 2022

CIS Pharma at Bio Europe in Leipzig

Leipzig, Germany, Monday, October 24 - CIS Pharma will attend Bio- Europe, the gateway to the global biopharma community. The team is looking forward to an exciting programme including vital industry topics such as AI, pharmaceuticals, preventative medicine, big data and more. Also Christian Geraths, CSO and Christoph Schäfer, CEO have planned a number of meetings to foster partnerships [...]

510, 2022

CIS Pharma at Congress of European Association of Nuclear Medicine, EANM, in Barcelona

Barcelona, Spain, Saturday, October 15, 2022 – CIS Pharma will attend the 35th Annual Congress of the European Association of Nuclear Medicine in Barcelona. The team is looking forward to learn more from world-leading physicians about the current clinical practice of radionuclide therapies and the perspectives and challenges of that specific cancer treatment modality. Christian Geraths, CSO and Christoph [...]

410, 2022

Innosuisse grants further funding for the CIS Pharma radioligand program

Bubendorf, Switzerland, Tuesday, October 4, 2022 – Based on the successful developments in the radioligand program, CIS Pharma and the ETH Zürich were granted continued funding for their development collaboration. Significant progress was achieved with respect to the lead optimization of CIS Pharma’s anti-L1CAM antibody as well as the polymer carrier platform. The ETH Zürich, specifically its radiopharmaceutical division Paul [...]

2109, 2022

CIS Pharma at Sachs Biotech in Europe Forum in Basel

Basel, Switzerland, Wednesday, September 21, 2022 – CIS Pharma will attend the 22nd Annual Biotech in Europe Forum in Basel. Taking place during the Sachs Autumn Life Sciences Week, the team is looking forward to an exciting programme with speakers of the Biotech, Pharma and Financial industry. Christian Geraths, CSO and Christoph Schäfer, CEO have planned a number of [...]

1809, 2022

CIS Pharma performing pre-clinical study with radioligand targeting CD 171 with Lutetium 177

Bubendorf, Switzerland, Tuesday, September 18 - CIS Pharma has initiated the production of an antibody-radionuclide conjugate, ARC, based on its humanized lead anti-CD171 antibody. The ARC Lutetium-177, at a radionuclide-to-antibody ratio, RAR, of four. Lutetium-177 is attached to the antibody by a site-directed coupling technology. The efficacy of the of the ARC well be evaluated in a Xenograft Mouse study [...]

1509, 2022

CIS Pharma performing pre-clinical study with ADC targeting CD 171 with monomethyl auristatin E

Bubendorf, Switzerland, Wednesday, September 15, 2022 - CIS Pharma has initiated the production of an antibody-drug conjugate, ADC, based on its humanized lead anti-CD171 antibody. The ADC comprises monomethyl auristatin E, MMAE, at a drug-to-antibody ratio, DAR, of four. The toxins are attached to the antibody by a site-directed coupling technology. The efficacy of the ADCs will be evaluated in [...]

1808, 2022

CIS Pharma has tested successfully its lead antibody targeting CD 171 in a biodistribution study

Villigen, Switzerland, Thursday, August 18, 2022 - CIS Pharma and its partner at ETH, Zürich, the division for radiopharmaceuticals, Paul Scherrer Institute, PSI, have made significant progress in their radionuclide anticancer treatment program. The lead candidate of the anti CD 171 platform shows high uptake in tumor tissue whereas background in non-targeted tissues is low as expected. The biodistribution [...]

205, 2022

CIS Pharma at Swiss Biotech Day in Basel

Basel, Switzerland, Monday, May 2, 2022 - CIS Pharma will attend the Swiss Biotech Day in Basel, one of the leading biotechnology conferences in Europe. The team is looking forward to learn more about the global biotech industry in general and specifically about the status of the industry in Switzerland. Ignazio Cassis, the President of the Swiss Confederation, will address [...]

1403, 2022

CIS Pharma has identified lead candidates for the development of B7H3 nanobodies targeting CD 276

Bubendorf, Switzerland, Monday, March 14, 2022 - CIS Pharmas has identified two lead candidates for the development of the first nanobody polymer conjugate targeting B7H3, CD 276. Based on the results, upscale of nanobody production and optimization of the linker system is planned for the second half of 2022. In addition, proprietary monomers will be synthesized, serving as building [...]

312, 2021

Preclinical development of a novel radiopharmaceutical bioconjugate with the potential to cross the blood brain barrier

Bubendorf, Switzerland, Friday, December 3, 2021 – CIS Pharma and the University of Applied Sciences in Basel were granted a two-year research program by the Swiss Nanoscience Institute, SNI, to develop a nanobody-radionuclide conjugate, currently at preclinical stage. The bioconjugate is based on CIS Pharma’s polymer drug carrier technology and is developed to diagnose and treat B7H3-positive forms of cancer. [...]

2211, 2021

Feasibility study initiated to develop a novel drug carrier to deliver oligonucleotides, ASO and siRNA

Bubendorf, Switzerland, Monday, November 22, 2021 – CIS Pharma has initiated a feasibility study to develop a novel carrier to conjugate ASO and siRNA for targeted delivery, in collaboration with the University of Applied Sciences in Basel. To widen the therapeutic use of oligonucleotides, CIS Pharma is developing technology for bio-conjugation of RNAi to targeting moieties, similar to the targeting [...]

506, 2021

Patent application published covering novel technology to improve contact lens care solutions

Bubendorf, Switzerland, Saturday, June 5, 2021 - CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS Pharma’s innovation reduces the trade-off between efficacy and safety, inherent to MPDS that cover the complete contact lens care regimen [...]

3105, 2021

Preclinical development of lead antibody-radionuclide conjugate targeting L1CAM to treat cancer patients resistant to chemotherapy

Bubendorf, Switzerland, Monday, May 31, 2021 - CIS Pharma and the Paul Scherrer Institute of ETH were granted a two-year research program by Innosuisse to develop an antibody-radionuclide conjugate, ARC, at pre-clinical stage. The ARC is based on CIS Pharma’s polymer drug carriers to diagnose and treat L1CAM-positive forms of cancer. In addition, the research partners will investigate CIS Pharma’s [...]

2605, 2021

Patent granted in USA for CIS Pharma novel contact lens coating technology

Bubendorf, Switzerland, Wednesday, May 26, 2021 - CIS Pharma has developed a coating technology to improve the comfort of silicone hydrogel contact lenses. The technology is based upon a block-copolymer technology comprising a hydrophilic and a hydrophobic part. The co-polymer is used for a non-covalent, adhesive interaction with the silicone part of silicone-hydrogel contact lens to form a hydrophilic [...]

2005, 2021

Development of nanobody conjugate to cross blood brain barrier and treat brain tumors

Bubendorf, Switzerland, Thursday, May 20, 2021 - CIS Pharma has started the development of a nanobody against a novel tumor target. The antigen is homogeneously overexpressed in various forms of cancer, such as glioblastoma, lung or colorectal cancers and usually related to poor prognosis. The novel nanobody is developed to serve as a basis for CIS Pharma’s nanobody-polymer conjugates targeted [...]

1202, 2021

CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier

Bubendorf, Switzerland, Friday, February 12, 2021 - CIS Pharma has initiated the development of a humanized monoclonal antibody against the target L1CAM / CD 171. L1CAM is a surface protein that is overexpressed in ovarian, colorectal, lung and other forms of cancer, with a fast progression of the disease, a high spread of metastases and therefore poor prognosis. The antibody [...]

2701, 2021

Connected eye-drop dispenser development to achieve feasibility based on micro-dosing technology

Bubendorf, Switzerland, Wednesday, January 27, 2021 - CIS Pharma has achieved feasibility for its connected eye-drop dispenser by successfully evaluating micro-dosing technology for controlled and precise dispensing of an ophthalmic formulation treating dry eye disease. Uniformity of dispensed drops was achieved at a standard deviation of 1.2% at drop sizes as small as 10ul. CIS Pharma offers a platform of [...]

812, 2020

CIS Pharma demonstrates successful in-vivo biodistribution study for Oncology drug carrier

Bubendorf, Switzerland, Tuesday, December 8, 2020 - CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a SKOvip mouse model, an aggressive form of ovarian cancer. The ARC tested comprised Trastuzumab as a model antibody to which two polymer carriers were conjugated that contained several [...]

612, 2020

CIS Pharma contact lens care solution shows enhanced biocompatibility, unsurpassed concentration of hyaluronic acid and a powerful disinfection complex

Bubendorf, Switzerland, Sunday, December 6, 2020 - CIS Pharma has successful up-scaled the production of its novel contact lens multipurpose and disinfection solution (MPDS) to an industrial setup. The contact lens care solution achieved excellent performance compared to products that are leading the markets. From an efficacy perspective, the antimicrobial performance against various bacteria & fungi was tested according to [...]

1510, 2020

CIS Pharma demonstrates in-vitro proof of concept for its ’s Oncology drug delivery technology

Bubendorf, Switzerland, Thursday, October 15, 2020 - CIS Pharma’s drug carrier technology has reached invitro proof of concept. A model antibody (Trastuzumab) was conjugated to two polymer carriers that were loaded with radioactive lucetium-177. The subsequent radioactive cell culture test (LINDMO method) showed that the affinity of CIS Pharma antibody radionuclide conjugate (ARC) to its target was similar compared to [...]

1405, 2020

CIS Pharma identifies lead polymer carrier for Oncology

Bubendorf, Switzerland, Thursday, May 14, 2020 - CIS Pharma’s polymer expert team has successfully reached the next milestone in its synthesis of the lead polymer carrier. Both analytical protocols as well as upscaling of the polymer technology has been established. “The quality and scale we have established is more than sufficient to enter into invivo studies” says Dr. Christophe Thommen, [...]

204, 2020

CIS Pharma Corona update

Bubendorf, Switzerland, Thursday, April 2, 2020 - CIS Pharma’s pipeline developments will experience some delay as a result of the Corona lock downs. Our Campus remains fully operational due to adequate space as well as due to efficient hygiene concepts. Unfortunately, some of our development partners had to face more stringent policies. We wish all of our partners to stay [...]

302, 2020

CIS Pharma attends EMSO sarcoma symposium in Milano

Milano, Italy, Monday February 3 to Wednesday February 5, 2020 - CIS Pharma attends the sarcoma symposium of the European Society for Medical Oncology, EMSO, in Milano. The event is a highly specialized meeting bringing together medical minds working on these tumor types. The symposium offered a good platform for CIS Pharma to discuss its oncology pipeline with known oncologists [...]

2301, 2020

CIS Pharma team attends the World Economic Forum in Davos

Davos, Switzerland, Thursday, January 23, 2020 – CIS Pharma attends the World Economic Forum in Davos, Switzerland. The main interest is to meet with its tracking technology partner modum.io and to attend the event provenance and transparency held at the Hotel Intercontinental in Davos. Tools against counterfeiting and instruments to create transparency in the value chain are two key areas [...]

Nach oben